NYSEAMERICAN:AZTR Azitra Q3 2025 Earnings Results & Report $0.13 0.00 (-1.59%) Closing price 04:10 PM EasternExtended Trading$0.13 0.00 (-0.69%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Azitra beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.67 versus the -$0.79 consensus estimate. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market OpensConference Call7:00 AM ET Azitra EPS ResultsActual EPS-$0.67Consensus EPS -$0.79Beat/MissBeat by +$0.12One Year Ago EPSN/AEPS Beat Rate2 of last 5 quartersAzitra Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAzitra's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Azitra Q3 2025 Earnings FAQ Did Azitra beat earnings estimates for Q3 2025? Azitra (NYSEAMERICAN:AZTR) reported earnings of -$0.67 per share for Q3 2025, beating the consensus estimate of -$0.79. The report was announced on Wednesday, November 12, 2025. When is Azitra's next earnings date? Azitra's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Azitra on the company's earnings history page. Azitra Earnings HeadlinesAzitra consensus price target decreased by 13.55% to $0.68October 2, 2026 | msn.comAzitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee ClearanceOctober 1, 2026 | prnewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 9 at 1:00 AM | Stansberry Research (Ad)Equities Analysts Offer Predictions for Azitra Q3 EarningsOctober 1, 2026 | americanbankingnews.comAzitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Drop in Short InterestSeptember 29, 2026 | americanbankingnews.comAzitra Launches At-the-Market Equity Offering ProgramSeptember 28, 2026 | tipranks.comSee More Azitra Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email. Email Address About AzitraAzitra (NYSEAMERICAN:AZTR) is a clinical-stage biotechnology company focused on developing live biotherapeutic products for dermatological conditions. The company uses microbiome science and genetic engineering to develop beneficial bacteria designed for topical application to the skin. Azitra’s research programs have focused on conditions including atopic dermatitis, acne vulgaris and other skin disorders associated with impaired barrier function or microbial imbalance. Its pipeline has included engineered strains of skin-associated bacteria intended to deliver therapeutic proteins or other biological effects directly to affected areas. The company was founded in 2014 and is based in New Haven, Connecticut. Its development programs are primarily aimed at the dermatology market, although detailed information about commercial operations, geographic reach and current leadership may change as the company advances its pipeline.View Azitra ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
